UPDATE: Wedbush Upgrades Ironwood Pharmaceuticals to Neutral on LINZESS Strength

Wedbush upgraded Ironwood Pharmaceuticals (NASDAQ: IRWD ) from Underperform to Neutral and raised the price target from $11.00 to $13.00. Wedbush said, "Early script data for Q1:13 (5 weeks) suggests strong week-over-week LINZESS performance (20,000+ pills per week growth), which, if sustained, would see Q1 and FY:13 end-user demand well